bluuebunny/crossref_metadata_2025_split huggingface dataset:
Comparison of Brachial Compression Versus Ulnar Compression on Radial Artery Diameter: A Randomized Controlled Trial
Authors: Bahrami Fatemeh , Mirshafiee Shayan , Mansouri Pejman , Eftekhari Mohammadreza , Vahidi Mohammad , Baharvand Fateme , Farsani Ehsan Moradi , Vahidi Hamed 
Published: November 2024

Objectives: This study is aimed at comparing the effectiveness of ulnar compression and brachial compression in inducing radial artery dilatation.Methods: This randomized crossover study included 30 patients undergoing elective diagnostic transradial coronary angiography. Ulnar compression and brachial compression maneuvers were performed in two groups. Radial artery diameter and cross‐sectional area were measured at baseline and remeasured every 30 s (up to 2 min) after the interventions.Results: Both ulnar compression and brachial compression maneuvers successfully increased radial artery diameter for up to 60 s following the interventions. There were no statistically significant differences between the two groups after adjusting for baseline measurements. However, each treatment group showed a significant increase in indicators up to 60 s, followed by a subsequent decrease. The maximum radial artery diameter occurred at 60 s after the removal of compression in both groups.Conclusion: Ulnar compression and brachial compression maneuvers demonstrated effectiveness in inducing radial artery dilation for a limited duration. These maneuvers may reduce the occurrence of access failure during radial artery cannulation. No significant differences were observed between the two maneuvers, indicating that they can be used interchangeably based on clinician preference. So, because the ulnar compression is simpler and more feasible for the patients, it can be considered instead of brachial compression.Trial Registration:IRCT20230209057372N1.
Comparative Analysis of Big Five Personality Traits and Emotional Regulation as Predictors of Happiness Among Nursing Students in Jordan and Saudi Arabia
Authors: Shdaifat Emad , Shudayfat Tamadur , Alshowkan Amira 
Published: November 2024

Background: Happiness is crucial for human wellbeing. Nursing students encounter distinct challenges such as stress, burnout, and emotional exhaustion, which can negatively impact their mental health. Cultural and societal factors also influence happiness.Objective: This study conducted a comparative analysis of Big Five personality traits and emotional regulation (ER) as predictors of happiness among nursing students in Saudi Arabia and Jordan.Methods: This cross‐sectional study included 739 nursing students from Jordan and Saudi Arabia who were selected using a multistage sampling technique. The instruments utilized in this study were the short version of the Big Five Inventory for assessing personality, Oxford Happiness Inventory for measuring happiness levels, and Emotional Regulation Questionnaire for evaluating ER. To identify the predictors of student happiness, stepwise regression analysis was conducted, and cross‐country comparisons were made using a “pool analysis” method.Results: The findings indicated that 62.1% of the participants reported moderate levels of happiness, whereas 36.0% reported high levels. There were significant differences in happiness levels between Jordan and Saudi Arabia (p = 0.003), with Jordanian students reporting lower happiness levels. In Saudi Arabia, there were significant variations based on age (p = 0.049) and academic year (p = 0.013). Multiple regression analysis revealed that higher agreeableness, extraversion, and conscientiousness were positively associated with happiness while openness had a weak association. Conversely, higher Neuroticism, being in Jordan, and being male were negatively associated with happiness. Nominal regression analysis indicated that extraversion and agreeableness are significant predictors of higher levels of happiness, whereas neuroticism is associated with lower levels of happiness. Furthermore, males and non‐Saudis were more likely to report lower levels of happiness.Conclusion: This study revealed notable determinants of happiness among nursing students in Saudi Arabia and Jordan. ER, Big Five personality traits, and demographic factors play influential roles. Overall, the robust regression model emphasized the dependability of these findings, providing valuable insights for nursing education and interventions aimed at improving student wellbeing. From a practical standpoint, these findings can guide the development of personalized mental health support programs and interventions designed to enhance the happiness and wellbeing of nursing students.
CD40 Agonist on Patient-Derived Xenograft Mice for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Authors: Bellaye Pierre-Simon , Georgievski Aleksandra , Ballerini Paola , Bouslama Boutheina , Richard Corentin , Boidot Romain , Chevreux Guillaume , Legros Véronique , Guy Julien , Racine Jessica , Collin Bertrand , Garrido Carmen , Quéré Ronan 
Published: November 2024

Abstract

Purpose:
Cluster of differentiation 40 (CD40) is expressed on B-cell acute lymphoblastic leukemia (B-ALL) cases. However, the effect of CD40 activation on B-ALL cells has never been tested in vivo.

Experimental Design:
The aim of our preclinical study was to investigate the therapeutic potential of a CD40 agonist in the treatment of B-ALL using patient-derived xenograft mouse models.

Results:
Intravenous administration of the CD40 agonist significantly impeded B-ALL cell proliferation and growth in vivo, accompanied by rapid activation of the ERK pathway, which led to the induction of apoptosis and disruption of cell-cycle progression. Cotreatment with a specific inhibitor of ERK further demonstrated that CD40 stimulation induced the proapoptosis of B-ALL cells in an ERK-dependent manner. Proteomic analysis revealed alterations in key signaling pathways associated with B-ALL expansion and maintenance. Moreover, the CD40 agonist markedly reduced the frequency of leukemia-initiating cells and leukemia development in patient-derived xenograft mice. Our study showed that the CD40 agonist can be associated with chemotherapeutic agents such as vincristine and dexamethasone, and this combination showed improved effectiveness. Additionally, the CD40 agonist was more effective on pre–B-ALL (EGIL B-III) that expressed CD40 than on common B-ALL (EGIL B-II) that lacked CD40 expression.

Conclusions:
These findings suggest that CD40 agonists are promising immunotherapeutic candidates for pediatric B-ALL, warranting further clinical investigations to improve patient outcomes in CD40-expressing B-ALL.
Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex
Authors: Schultz Kris Ann P. , MacFarland Suzanne P. , Perrino Melissa R. , Mitchell Sarah G. , Kamihara Junne , Nelson Alexander T. , Mallinger Paige H.R. , Brzezinski Jack J. , Maxwell Kara N. , Woodward Emma R. , Gallinger Bailey , Kim Sun Young , Greer Mary-Louise C. , Schneider Kami Wolfe , Scollon Sarah R. , Das Anirban , Wasserman Jonathan D. , Eng Charis , Malkin David , Foulkes William D. , Michaeli Orli , Bauer Andrew J. , Stewart Douglas R. 
Published: November 2024

Abstract
Phosphate and tensin homolog hamartoma tumor syndrome, DICER1-related tumor predisposition, and tuberous sclerosis complex are rare conditions, which each increases risk for distinct spectra of benign and malignant neoplasms throughout childhood and adulthood. Surveillance considerations for each of these conditions focus on patient and family education, early detection, and multidisciplinary care. In this article, we present updated surveillance recommendations and considerations for children and adolescents with phosphate and tensin homolog hamartoma tumor syndrome, DICER1-related tumor predisposition, and tuberous sclerosis complex and provide suggestions for further research in each of these conditions.
Abstract A006: Development of a syngeneic transplant rat model for the identification of an mRNA signature associated with metastatic hepatocellular carcinoma
Authors: Azcárraga Acosta Theresa G , Vazquéz Carolina Piña , Hernández Galdámez Hury V , Rubio Nava Karla M , Linares Josué Guzmán , Díaz Ivonne Ramírez , Barreto Guillermo , Aguilar Chaparro Mario A , Günther Stefan , Treviño Saul Villa , De la Garza Mireya , Téllez Teresita del niño Jesús Flores , Vásquez Garzón Veronica R 
Published: November 2024

Abstract
Approximately 70% of patients with hepatocellular carcinoma (HCC) die of metastasis, mainly in the lung, due in part to late diagnosis. Therefore, in vivo models that are representative of metastatic HCC biology in patients must include factors that are essential for metastasis development, such as an immunocompetent system and a tumor microenvironment with homotypic interactions. This will allow the identification of new prognostic biomarkers for patients with metastatic HCC that are efficient and accessible. We developed two hepatocellular carcinoma cell lines for syngeneic transplant models in immunocompetent rats: Samy (nonmetastatic) and Samy Met (metastatic). These cell lines allow the development of cancer and metastasis in a homotypic environment with a complete immune system; therefore, they are expected to be representative of what happens in patients with metastatic HCC. Both cell lines were biologically characterized, and the primary tumors they produced were used in a comparative transcriptomic study to identify a metastatic HCC molecular signature that may function as a prognostic biomarker. The differentially expressed genes (DEGs) were related to relevant biological processes, such as metastasis, cancer stem cells (CSCs), and tumor growth, and all of these processes are essential for cancer progression. Among the top 50 DEGs, an mRNA firm was assembled, including 3 upregulated genes (ITGB6, SEMA3F, and NDC80) and 7 downregulated genes (COL15A1, ATP13A4, C18ORF26, PRKG2, ITM2A, IGSF9B, and CNTN1). The firm was related to poor survival in patients with HCC and had good accuracy in predicting macrovascular invasion, which is a strong predictor of poor HCC outcome, both after surgical resection and after liver transplantation.
Citation Format: Theresa G Azcárraga Acosta, Carolina Piña Vazquéz, Hury V Hernández Galdámez, Karla M Rubio Nava, Josué Guzmán Linares, Ivonne Ramírez Díaz, Guillermo Barreto, Mario A Aguilar Chaparro, Stefan Günther, Saul Villa Treviño, Mireya De la Garza, Teresita del niño Jesús Flores Téllez, Veronica R Vásquez Garzón. Development of a syngeneic transplant rat model for the identification of an mRNA signature associated with metastatic hepatocellular carcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr A006.
Abstract A011: Binding of the exon junction complex shapes the landscape of m6A in RNA - a possible source of m6A dysregulation in cancer
Authors: Price Andrew , Sendinc Erdem , Purse Byron , Gregory Richard I , Stengel Gudrun 
Published: November 2024

Abstract
N6-methyladenosine (m6A) is the most prevalent modification in eukaryotic mRNA. Increasing evidence shows that m6A is involved in the biological functions of cancer cells, including proliferation, invasion, metastasis, and drug resistance. Dysregulation of m6A deposition and its associated machinery, including writers, erasers and readers, is observed in multiple cancer types, and the dysregulation profiles have potential as diagnostic, prognostic and/or predictive biomarkers. In healthy cells, m6A modifications are installed co-transcriptionally by the writer enzyme METTL3, resulting in an enrichment of m6A in the 3’UTR of genes. For many years, the mechanistic origin for the m6A enrichment in the 3’UTR was unclear. Recently, the Gregory lab and others have developed a model where the exon junction complex (EJC) plays a key role in directing m6A deposition by hindering access of METTL3 to short exons and exon/intron junctions. In this study, we build on this model using a novel, proximity-barcoding based assay (EpiPlex™) for the simultaneous detection of m6A and inosine. Working with HEK293T cells, we modulated the activity of a central component of the EJC, the RNA helicase EIF4A3. Both genetic knockdown and chemical inhibition of EIF4A3 resulted in increased m6A levels and more diffuse localization at the 3’UTR. New m6A sites appear on short exons and near exon/intron junctions. These data corroborate the necessity of EIF4A3 for EJC assembly and confirm the model that the EJC prevents METTL3 from accessing and methylating exon junctions. Additionally, we find that blocking of the exon junction is reliant on EIF4A3’s helicase activity. Although the role of EJC in the cell cycle and cancer are still investigational, it is likely that m6A dysregulation is induced by aberrant EJC function, which presents a potential molecular mechanism for the dysregulation of multiple genetic pathways in cancer progression.
Citation Format: Andrew Price, Erdem Sendinc, Byron Purse, Richard I Gregory, Gudrun Stengel. Binding of the exon junction complex shapes the landscape of m6A in RNA - a possible source of m6A dysregulation in cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr A011.
Abstract A030: Beyond the LNP: Self-amplifying RNA with LION nanoformulation technology for development of safe and effective cancer therapeutics
Authors: Berglund Peter 
Published: November 2024

Abstract
HDT Bio, a Seattle biotech company, has developed a platform technology based on self-amplifying RNA and a proprietary nanoparticle delivery system. mRNA have been increasingly used in the development of vaccines in both infectious diseases and oncology. Especially LNP- delivered mRNA has been deployed, following the success during the COVID pandemic, However, self-ampliying RNA (repRNA) possesses several features of particular relevance to cancer medicine. HDT has developed a nanoparticle technology named LION[TM] to safely and effectively deliver RNA to patients. In vivo studies showed that repRNA not only is capable of delivering robust cell-mediated immune responses but also doing so with a significanlty improved safety profile compared to administration using LNP-based formulations. These data will be presented in the context of clinical safety data with repRNA/LION. Furthermore, repRNA/LION was siuccessfully used to induce robust T-cell responses against tumor antigens, and will be discussed.
Citation Format: Peter Berglund. Beyond the LNP: Self-amplifying RNA with LION nanoformulation technology for development of safe and effective cancer therapeutics [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr A030.
Abstract B001: CircRNA-derived neoantigen identification in cancer vaccine development
Authors: Zheng Yi-Cian , Chen Chun-Kan 
Published: November 2024

Abstract
Immunotherapy has been a popular topic in combating cancer for its great performance in specificity, versatility and durability recently. Cancer vaccines targeting neoantigens have shown clinical efficacy against cancer, eliciting long-lasting immune response and offering a more selective therapeutic approach with less side effects. However, rare mutation rates and low expression levels of neoantigen make it challenging to identify suitable neoantigens. Traditionally, researchers focus on the canonical mRNA transcriptome and proteome to find potential targets. Recent studies suggest that exploring the non-canonical transcriptome and proteome, particularly circular RNAs (circRNAs), can expand the search. CircRNAs, endogenously formed by the unique back-splicing events during pre-RNA processing, can serve as templates for protein synthesis. Some of these non-canonical peptides are specifically expressed in cancer cells, making circRNAs a valid source for neoantigen discovery. We have developed high-throughput circRNA reporter screening methods and mass spectrometry-based peptidomic workflow to pinpoint translating circRNAs and their derived peptides. Using these techniques, we have identified circRNA-derived neoantigens in breast cancer (BC) cell lines that can be used as possible targets for cancer vaccines. These circRNA-derived neoantigens are immunogenic and can trigger dendritic cell (DC) maturation and T cell activation in vitro. Next, we will test these findings by transferring to in vivo mouse system. We will assess cancer vaccine efficacy by targeting the neoantigens using syngeneic mouse tumor models. Our long- term goal is to apply the circRNA neoantigen identification technology to BC patient samples to facilitate cancer vaccine development and improve cancer immunotherapy. Our work will demonstrate the potential of circRNA-derived non canonical neoantigens in cancer vaccines, serving as a crucial first step to prove their effectiveness in therapy. By expanding our search beyond the traditional transcriptome and proteome, we will explore new targets and transform the neoantigen-based treatment. This innovative effort shifts the current understanding of neoantigen sources and opens up new possibilities for targeted cancer therapy strategies.
Citation Format: Yi-Cian Zheng, Chun-Kan Chen. CircRNA-derived neoantigen identification in cancer vaccine development [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr B001.
Abstract I001: Long noncoding RNAs at the intersection of cancer pathways
Authors: Dimitrova Nadya 
Published: November 2024

Abstract
There are thousands of long noncoding RNAs (lncRNAs) in mammalian genomes. Yet, their functional significance in health and disease states remains poorly understood. We investigate the intersection of lncRNAs and cancer biology. On the one hand, we dissect the molecular and cellular mechanisms by which lncRNAs modulate cancer pathways. On the other hand, we develop mouse models to interrogate the roles of lncRNAs in tumorigenesis at the organismal level. Our work has uncovered insights into the transcriptional regulatory roles of lncRNAs during the cellular response to genotoxic and oncogenic stress. In parallel, we have elucidated roles of lncRNAs as drivers of tumor progression and metastatic dissemination. The combined functional and mechanistic studies have revealed the importance of lncRNAs in cancer and suggest therapeutic approaches to target lncRNAs or their downstream effectors in cancer.
Citation Format: Nadya Dimitrova. Long noncoding RNAs at the intersection of cancer pathways [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr I001.
Abstract I005: Exploiting the immunoregulatory effect of double-stranded RNAs for cancer therapeutics
Authors: Lee Keonyong , Ku Jayoung , Widowati Tria Asri , Kim Namwook , Park Soo Young , Ryu Han Suk , Kim Yoosik 
Published: November 2024

Abstract
Introns are found in all eukaryotes and are one of the defining characteristics of eukaryotes. After transcription, pre-mRNAs undergo splicing, and introns are excised in the lariat structure. Since excised introns are degraded quickly after debranching, they have been considered as byproducts of gene expression, and their post-splicing role in the cells remains unclear. Here, we find that the inhibition of intron debranching process by depleting a debranching enzyme, DBR1, results in hyperactivation of protein kinase R (PKR) due to accumulation of intron lariat-derived transposable elements (TEs) that can adopt double-stranded secondary structure. Through in vitro PKR-binding assay, we show that PKR strongly binds to intron lariat RNAs harboring TEs, especially inverted Alu repeats. Interestingly, these TE-containing lariat RNAs are retained in the nucleus, but are released to the cytosol during mitosis, where they activate PKR, resulting in aberrant mitotic progression and apoptosis. We further exploit the lariat RNA-PKR interaction during mitosis and show that DBR1 depletion and anti-mitotic chemotherapy drugs can synergistically induce cancer cell death both in vitro and in vivo. Lastly, we perform docking simulation-based screening of DBR1-inhibitory small molecules. Collectively, our findings underscore the significance of intron turnover in avoiding innate immune activation and further suggest a potential strategy to enhance the efficacy of anti-mitotic drugs by targeting intron processing.
Citation Format: Keonyong Lee, Jayoung Ku, Tria Asri Widowati, Namwook Kim, Soo Young Park, Han Suk Ryu,Yoosik Kim. Exploiting the immunoregulatory effect of double-stranded RNAs for cancer therapeutics [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer; 2024 Nov 14-17; Bellevue, Washington. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(11_Suppl):Abstract nr I005.